Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling ASPENOVA designed as confirmatory study to support DENALI Phase 2 accelerated approval...
SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor...
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...
While Zentalis’ dose selection marks a significant clinical milestone, the underlying data suggests that Aprea’s APR-1051 may offer a superior therapeutic profile by maintaining daily dosing
Preclinical data show encouraging activity of azenosertib combinations in ADC-resistant TNBC, supporting the potential for pipeline expansion beyond ovarian cancer Real-world data demonstrate Cyclin...
Aprea Therapeutics (APRE) recently showcased positive preliminary Phase 1 data for its next-generation WEE1 inhibitor, APR-1051, highlighting early tumor reduction in biomarker-defined cancer
Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groups Azenosertib therapeutic...
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1...
On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval On track to initiate the ASPENOVA Phase...
Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer  Demonstration of Cyclin E1 protein overexpression...